Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteome profilling of chromophobe renal cell carcinomas

ABSTRACT: LC-MS/MS based proteomics study of chromophobe renal cell carcinomas versus the adjacent healthy kidney tissues, nine patients included. The chromophobe renal cell carcinoma cells (UOK276) under different conditions were also analyzed.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Permanent Cell Line Cell, Chromophobe Renal Cell Carcinoma Cell, Kidney

DISEASE(S): Chromophobe Renal Cell Carcinoma

SUBMITTER: Yi Xiao

LAB HEAD: David Meierhofer

PROVIDER: PXD019123 | Pride | 2020-07-23

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	UOK276_100AA_no_BSA_1_1D.index	Other
	UOK276_100AA_no_BSA_1_1D.raw	Raw
	UOK276_100AA_no_BSA_1_SCX_3.index	Other
	UOK276_100AA_no_BSA_1_SCX_3.raw	Raw
	UOK276_100AA_no_BSA_1_SCX_4.index	Other

Items per page:

1 - 5 of 198

Publications

Decreased Mitochondrial DNA Content Drives OXPHOS Dysregulation in Chromophobe Renal Cell Carcinoma.

Xiao Yi Y Clima Rosanna R Busch Jonas J Rabien Anja A Kilic Ergin E Villegas Sonia L SL Timmermann Bernd B Attimonelli Marcella M Jung Klaus K Meierhofer David D

Cancer research 20200721 18

Chromophobe renal cell carcinoma (chRCC) and renal oncocytoma are closely related, rare kidney tumors. Mutations in complex I (CI)-encoding genes play an important role in dysfunction of the oxidative phosphorylation (OXPHOS) system in renal oncocytoma, but are less frequently observed in chRCC. As such, the relevance of OXPHOS status and role of CI mutations in chRCC remain unknown. To address this issue, we performed proteome and metabolome profiling as well as mitochondrial whole-exome sequen ...[more]

PMID: 32694149

Similar Datasets

proteome profilling of chromophobe renal cell carcinomas

Project description:LC-MS/MS based proteomics study of chromophobe renal cell carcinomas versus the adjacent healthy kidney tissues, ten patients included.

2022-03-03 | PXD010391 | Pride

Chromophobe renal cell carcinoma versus renal oncocytoma: a proteomic approach

Project description:The proteome of clinical tissue samples diagnosed with chromophobe renal cell carcinomas (chRCC) and renal oncocytomas (RO) were evaluated to establish a potential discriminative biomarker panel of proteins for these two tumors subtypes.

2024-01-26 | PXD022018 | Pride

Development of a DNA methylation-based diagnostic signature to distinguish benign oncocytoma from renal cell carcinoma

Project description:We profiled DNA methylation in fresh-frozen oncocytoma and chRCC tumors and tumor-adjacent adjacent normal tissue to identify a signature of differentially methylated CpG sites that robustly distinguish oncocytoma from chRCC. DNA methylation profiles were generated for renal oncocytomas (n=12), primary kidney chromophobes (chRCC) (n=8) and primary kidney clear cell carcinomas (ccRCC) (n=2). Also profiled were three oncocytic neoplasms of unclear pathological diagnosis, including two masses described as hybrid oncocytic/chromophobe type (n=2), and one mass described as hybrid oncocytic renal neoplasm. Also profiled were histologically normal adjacent kidney parenchyma tissue (NKP) from a subset of these patients, including NKP from oncocytoma (n=7), chRCC (n=5), ccRCC (n=1), hybrid oncocytic/chromophobe type (n=1), and hybrid oncocytic renal neoplasm (n=1) bearing kidneys (combined n=15 NKP).

2020-09-30 | GSE156932 | GEO

Clear-cell renal cell carcinomas tumors

Project description:Whole genome expression of 39 clear-cell renal cell carcinomas tumors

2011-05-28 | GSE29609 | GEO

Genomics of pediatric renal medullary carcinomas

Project description:Genomics of pediatric renal medullary carcinomas

| PRJNA528529 | ENA

Genomics of pediatric renal medullary carcinomas

Project description:Genomics of pediatric renal medullary carcinomas

| PRJNA528528 | ENA

microRNA profiling in renal carcinoma

Project description:Renal cell carcinoma comprises a variety of entities, the most common being the clear-cell, papillary and chromophobe subtypes. These subtypes are related to different clinical evolution; however, most therapies have been developed for clear-cell carcinoma and there is not a specific treatment based on different subtypes. In this study, one hundred and sixty-four paraffin samples from primary nephrectomies for localized tumors were analyzed. MiRNAs were isolated and measured by microRNA arrays. Significance Analysis of Microarrays and Consensus Cluster algorithm were used to characterize different renal subtypes. The analyses showed that chromophobe renal tumors are a homogeneous group characterized by an overexpression of miR 1229, miR 10a, miR 182, miR 1208, miR 222, miR 221, miR 891b, miR 629-5p and miR 221-5p. On the other hand, clear cell renal carcinomas presented two different groups inside this histological subtype, with differences in miRNAs that regulate focal adhesion, transcription, apoptosis and angiogenesis processes. Specifically, one of the defined groups had an overexpression of proangiogenic microRNAs miR185, miR126 and miR130a. In conclusion, differences in miRNA expression profiles between histological renal subtypes were established. In addition, clear cell renal carcinomas had different expression of proangiogenic miRNAs. With the emergence of antiangiogenic drugs, these differences could be used as therapeutic targets in the future or as a selection method for tailoring personalized treatments.

2020-03-01 | GSE144082 | GEO

Clear-cell renal cell carcinomas tumors

Project description:Whole genome expression of 39 clear-cell renal cell carcinomas tumors 39 frozen tissue from recent nephrectomies for clear-cell renal cell carcinoma; association with clinical characteristics

2011-05-28 | E-GEOD-29609 | biostudies-arrayexpress

Genome-wide methylation analysis of tubulocystic and papillary renal cell carcinomas

Project description:Tubulocystic renal cell carcinoma (TRCC) represents a rare tumor with incidence lower than 1 % of all renal carcinomas. This study was undertaken to contribute to characterization of molecular signatures associated with TRCC and to compare them with the features of papillary renal cell carcinoma (PRCC) at the level of genome wide methylation analysis. We performed methylated DNA immunoprecipitation (MeDIP) coupled with microarray analysis (Roche NimbleGen). Using bioinformatics approach, we compared the levels of gene methylation between paired samples of tumors and control renal tissues of each examined individual. We found significant global demethylation in all tumor samples in comparison with adjacent kidney tissues of normal histological appearance but no significant differences in gene methylation between the both compared tumor entities. Therefore we focused on characterization of differentially methylated regions between both tumors and control tissues. We found 42 differentially methylated genes. Hypermethylated genes for protocadherins (PCDHG) and genes coding for products associated with functions of plasma membrane were evaluated as significantly overrepresented among hypermethylated genes detected in both types of renal cell carcinomas. We provided the evidence that identical features in the process of carcinogenesis leading to TRCC and/or to PRCC may be found at the gene methylation level.

2016-01-15 | E-MTAB-2829 | biostudies-arrayexpress

Transcription profiling by array of human chromophobe renal cell carcinoma and oncocytoma

Project description:This study aims to compare gene expression profiles of chromophobe renal cell carcinoma (RCC) and benign oncocytoma, aiming at identifying differentially expressed genes. Experiment Overall Design: Nine cases each of chromophobe RCC and oncocytoma were analyzed by oligonucleotide microarray. Candidate genes that showed consistent differential expression were validated by RT-PCR using 25 fresh-frozen and 15 formalin-fixed paraffin-embedded tumor samples. Immunohistochemical analysis was also performed for two selected gene products, Claudin 8 and MAL2.

2008-10-21 | E-GEOD-12090 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data